Journal: Gastro Hep Advances

Article Title: Cannabinoids Block Fat-induced Incretin Release via CB 1 -dependent and CB 1 -independent Pathways in Intestinal Epithelium

doi: 10.1016/j.gastha.2024.07.006

Figure Lengend Snippet: Exogenous activation of peripheral CB 1 Rs blocks fat-induced GIP and aGLP1 secretion. Compared to the control (0.5 mL saline by oral gavage and vehicle by IP injection), corn oil (CO; 0.5 mL by oral gavage) increased levels of the incretins GIP [treatment effect F (3,17) = 10.53, P = .0004] (A) and active GLP1 [treatment effect F (3,17) = 18.06, P < .0001] (B) but did not significantly increase levels of plasma insulin (C) in plasma of fasted mice. This effect was blocked by pretreatment with CB 1 R agonist, WIN 55,212-2 (WIN, IP 3 mg per kg 30 minutes before CO). The inhibitory effects of WIN on incretins were inhibited by coadministration with the peripherally-restricted CB 1 R antagonist, AM6545 (AM; IP 10 mg per kg 30 minutes before CO). Data expressed as means ± S.E.M. and analyzed by one-way ANOVA with post hoc Holm-Sidak multiple comparison tests. n = 4–6 per condition, ∗ P < .05, ∗∗ P < .01, ∗∗∗ P < .001.

Article Snippet: Indeed, GLP1 mimetics (eg, semaglutide, liraglutide) reduce body mass in obese and diabetic patients, partly due to the hypophagic effects of activating GLP1 receptors.

Techniques: Activation Assay, Control, Saline, Injection, Clinical Proteomics, Comparison

Journal: Cureus

Article Title: Comparing Glucagon-Like Peptide-1 Receptor Agonists to Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Preserved Ejection Fraction: A Systematic Review

doi: 10.7759/cureus.78570

Figure Lengend Snippet: PubMed detailed search strategy MeSH: Medical Subject Headings

Article Snippet: 2 , TS=("glp-1 analog” OR “glp-1 analogs” OR “glp-1 analogs” OR “glp-1 receptor agonist” OR “glp-1 receptor agonists” OR “glp-1 receptor agonists” OR “glp-1 analog” OR “glp-1 analogs” OR “glp-1 analogs” OR “glp-1 receptor agonist” OR “glp-1 receptor agonists” OR “glp-1 receptor agonists” OR “glucagon like peptide 1 receptor agonist” OR “Glucagon-Like Peptide-1 Receptor Agonists” OR “Glucagon-Like Peptide-1 Receptor Agonists” OR “incretin mimetic” OR “incretin mimetics” OR “albiglutide” OR “tanzeum” OR “dulaglutide” OR “trulicity” OR “exenatide” OR “byetta” OR “bydureon” OR “bydureon bcise” OR “liraglutide” OR “victoza” OR “saxenda” OR “lixisenatide” OR “adlyxin” OR “semaglutide” OR “ozempic” OR “wegovy” OR “tirzepatide” OR “mounjaro” OR “zepbound”) , 18,326.

Techniques:

Journal: Cureus

Article Title: Comparing Glucagon-Like Peptide-1 Receptor Agonists to Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Preserved Ejection Fraction: A Systematic Review

doi: 10.7759/cureus.78570

Figure Lengend Snippet: Web of Science detailed search strategy

Article Snippet: 2 , TS=("glp-1 analog” OR “glp-1 analogs” OR “glp-1 analogs” OR “glp-1 receptor agonist” OR “glp-1 receptor agonists” OR “glp-1 receptor agonists” OR “glp-1 analog” OR “glp-1 analogs” OR “glp-1 analogs” OR “glp-1 receptor agonist” OR “glp-1 receptor agonists” OR “glp-1 receptor agonists” OR “glucagon like peptide 1 receptor agonist” OR “Glucagon-Like Peptide-1 Receptor Agonists” OR “Glucagon-Like Peptide-1 Receptor Agonists” OR “incretin mimetic” OR “incretin mimetics” OR “albiglutide” OR “tanzeum” OR “dulaglutide” OR “trulicity” OR “exenatide” OR “byetta” OR “bydureon” OR “bydureon bcise” OR “liraglutide” OR “victoza” OR “saxenda” OR “lixisenatide” OR “adlyxin” OR “semaglutide” OR “ozempic” OR “wegovy” OR “tirzepatide” OR “mounjaro” OR “zepbound”) , 18,326.

Techniques:

Journal: Cureus

Article Title: Comparing Glucagon-Like Peptide-1 Receptor Agonists to Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Preserved Ejection Fraction: A Systematic Review

doi: 10.7759/cureus.78570

Figure Lengend Snippet: Cochrane Central Register of Controlled Trials detailed search strategy

Article Snippet: 2 , TS=("glp-1 analog” OR “glp-1 analogs” OR “glp-1 analogs” OR “glp-1 receptor agonist” OR “glp-1 receptor agonists” OR “glp-1 receptor agonists” OR “glp-1 analog” OR “glp-1 analogs” OR “glp-1 analogs” OR “glp-1 receptor agonist” OR “glp-1 receptor agonists” OR “glp-1 receptor agonists” OR “glucagon like peptide 1 receptor agonist” OR “Glucagon-Like Peptide-1 Receptor Agonists” OR “Glucagon-Like Peptide-1 Receptor Agonists” OR “incretin mimetic” OR “incretin mimetics” OR “albiglutide” OR “tanzeum” OR “dulaglutide” OR “trulicity” OR “exenatide” OR “byetta” OR “bydureon” OR “bydureon bcise” OR “liraglutide” OR “victoza” OR “saxenda” OR “lixisenatide” OR “adlyxin” OR “semaglutide” OR “ozempic” OR “wegovy” OR “tirzepatide” OR “mounjaro” OR “zepbound”) , 18,326.

Techniques:

Journal: Therapeutic Advances in Endocrinology and Metabolism

Article Title: The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence

doi: 10.1177/2042018821989238

Figure Lengend Snippet: Main clinical studies of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in PCOS.

Article Snippet: We developed a search string of medical subject headings (MeSH) including the terms PCOS, incretin mimetics, glucagon-like peptide-1 (GLP-1), glucagon-like peptide-1 receptor antagonists (GLP-1 RAs), liraglutide, exenatide, semaglutide, dipeptidyl peptidase-4 (DPP-4) inhibitors, combined with IR, testosterone and sex hormone-binding globulin (SHBG).

Techniques: Control